144 related articles for article (PubMed ID: 29110833)
21. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
22. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Grönberg H
Leukemia; 2017 Oct; 31(10):2029-2036. PubMed ID: 28167833
[TBL] [Abstract][Full Text] [Related]
23. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
24. Should evaluation for minimal residual disease be routine in acute myeloid leukemia?
Coustan-Smith E; Campana D
Curr Opin Hematol; 2013 Mar; 20(2):86-92. PubMed ID: 23380603
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
26. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
27. Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia.
King RL; Bagg A
Methods Mol Biol; 2017; 1633():1-17. PubMed ID: 28735477
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
Buccisano F; Hourigan CS; Walter RB
Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
31. Next generation sequencing of acute myeloid leukemia: influencing prognosis.
Ilyas AM; Ahmad S; Faheem M; Naseer MI; Kumosani TA; Al-Qahtani MH; Gari M; Ahmed F
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S5. PubMed ID: 25924101
[TBL] [Abstract][Full Text] [Related]
32. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
Tomlinson B; Lazarus HM
Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
[TBL] [Abstract][Full Text] [Related]
33. Precision medicine for acute myeloid leukemia.
Lai C; Karp JE; Hourigan CS
Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
[TBL] [Abstract][Full Text] [Related]
34. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
35. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
Leisch M; Jansko B; Zaborsky N; Greil R; Pleyer L
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30795628
[TBL] [Abstract][Full Text] [Related]
36. Whole-exome sequencing enhances prognostic classification of myeloid malignancies.
Ruffalo M; Husseinzadeh H; Makishima H; Przychodzen B; Ashkar M; Koyutürk M; Maciejewski JP; LaFramboise T
J Biomed Inform; 2015 Dec; 58():104-113. PubMed ID: 26453823
[TBL] [Abstract][Full Text] [Related]
37. The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
[TBL] [Abstract][Full Text] [Related]
39. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
[TBL] [Abstract][Full Text] [Related]
40. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
